Vera Therapeutics (VERA) Capital Expenditures (2020 - 2026)
Vera Therapeutics posted quarterly Capital Expenditures of $23000.0 for Q1 2026, down 87.7% year-on-year from $187000.0 in Q1 2025, and down 77.45% on a QoQ basis from $102000.0 in Q4 2025.
Vera Therapeutics (VERA) has 6 years of Capital Expenditures data on file, last reported at $23000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 87.7% year-over-year to $23000.0; the trailing twelve-month figure through Mar 2026 stood at $466000.0 (down 59.79% YoY), and the FY2025 full-year result was $630000.0, down 35.19% from the prior year.
- Capital Expenditures for Q1 2026 stood at $23000.0, down from $102000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $645000.0 in Q4 2024 and bottomed at $6000.0 in Q2 2022.
- The 5-year median for Capital Expenditures is $95500.0 (2024), against an average of $145833.3.
- The widest annual swing landed in 2024, when Capital Expenditures jumped 923.81%; it then sank 87.7% in 2026.
- A 5-year view of Capital Expenditures shows it stood at $38000.0 in 2022, then surged by 65.79% to $63000.0 in 2023, then surged by 923.81% to $645000.0 in 2024, then slumped by 84.19% to $102000.0 in 2025, then plunged by 77.45% to $23000.0 in 2026.
- The last three Capital Expenditures figures came in at $23000.0 (Q1 2026), $102000.0 (Q4 2025), and $133000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Vera Therapeutics | 2.43 Bn | 1.83 Bn | - | 23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 102,000.00 |
| Dec 31, 2025 | 102,000.00 |
| Sep 30, 2025 | 133,000.00 |
| Sep 30, 2025 | 133,000.00 |
| Jun 30, 2025 | 208,000.00 |
| Jun 30, 2025 | 208,000.00 |
| Mar 31, 2025 | 187,000.00 |
| Mar 31, 2025 | 187,000.00 |
| Dec 31, 2024 | 645,000.00 |
| Dec 31, 2024 | 645,000.00 |
| Sep 30, 2024 | 238,000.00 |
| Sep 30, 2024 | 238,000.00 |
| Jun 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 89,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Sep 30, 2022 | 38,000.00 |
| Sep 30, 2022 | 38,000.00 |
| Jun 30, 2022 | 6,000.00 |
| Jun 30, 2022 | 6,000.00 |
| Mar 31, 2022 | 18,000.00 |
| Mar 31, 2022 | 18,000.00 |
| Jun 30, 2020 | 47,000.00 |
| Jun 30, 2020 | 47,000.00 |
| Mar 31, 2020 | 52,000.00 |
| Mar 31, 2020 | 52,000.00 |